Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Author:

Deng Yanhong1,Chi Pan2,Lan Ping1,Wang Lei1,Chen Weiqing3,Cui Long4,Chen Daoda5,Cao Jie6,Wei Hongbo7,Peng Xiang8,Huang Zonghai9,Cai Guanfu10,Zhao Ren11,Huang Zhongcheng12,Xu Lin13,Zhou Hongfeng14,Wei Yisheng15,Zhang Hao16,Zheng Jian1,Huang Yan1,Zhou Zhiyang1,Cai Yue1,Kang Liang1,Huang Meijin1,Wu Xiaojian1,Peng Junsheng1,Ren Donglin1,Wang Jianping1

Affiliation:

1. The Sixth Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, Guangzhou, People’s Republic of China

2. Fujian Medical University Union Hospital, Fuzhou, People's Republic of China

3. School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China

4. Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

5. Xiehe Hospital, Huazhong University of Science and Technology, Wuhan, China

6. The First People’s Hospital, Guangzhou City, People’s Republic of China

7. The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

8. The First People’s Hospital, Foshan City, People’s Republic of China

9. Zhujiang Hospital, Nanfang University of Medical Science, Guangzhou, People’s Republic of China

10. Guangdong Provincial Peoples Hospital, Guangzhou, People’s Republic of China

11. Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

12. General Hospital, Hunan Province, Changsha, People’s Republic of China

13. The First Affiliated Hospital, Xiamen University, Xiamen, People’s Republic of China

14. Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, People’s Republic of China

15. The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, People’s Republic of China

16. Xinhua Hospital, Dongguan, People’s Republic of China

Abstract

PURPOSE In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2.4 g/m2 over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m2 on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% ( P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% ( P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% ( P = .971 by log-rank test), respectively. CONCLUSION mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3